JP2014534205A - 非アセチル化タンパク質からのアセチル化タンパク質の分離 - Google Patents
非アセチル化タンパク質からのアセチル化タンパク質の分離 Download PDFInfo
- Publication number
- JP2014534205A JP2014534205A JP2014537042A JP2014537042A JP2014534205A JP 2014534205 A JP2014534205 A JP 2014534205A JP 2014537042 A JP2014537042 A JP 2014537042A JP 2014537042 A JP2014537042 A JP 2014537042A JP 2014534205 A JP2014534205 A JP 2014534205A
- Authority
- JP
- Japan
- Prior art keywords
- acetylated
- interferon
- group
- protein
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091005646 acetylated proteins Proteins 0.000 title claims abstract description 43
- 238000000926 separation method Methods 0.000 title description 18
- 238000000034 method Methods 0.000 claims abstract description 63
- 238000012433 multimodal chromatography Methods 0.000 claims abstract description 15
- 229940079322 interferon Drugs 0.000 claims description 36
- 108010050904 Interferons Proteins 0.000 claims description 34
- 102000014150 Interferons Human genes 0.000 claims description 34
- 238000004587 chromatography analysis Methods 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000007800 oxidant agent Substances 0.000 claims description 15
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 8
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 8
- 125000001165 hydrophobic group Chemical group 0.000 claims description 8
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000014616 translation Effects 0.000 claims description 7
- 238000005349 anion exchange Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000003196 chaotropic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- ZRXQJVNCDGGNMV-UHFFFAOYSA-M acetyl(trimethyl)azanium;chloride Chemical compound [Cl-].CC(=O)[N+](C)(C)C ZRXQJVNCDGGNMV-UHFFFAOYSA-M 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 239000012459 cleaning agent Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000005063 solubilization Methods 0.000 claims description 2
- 230000007928 solubilization Effects 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 1
- 108700004121 sarkosyl Proteins 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 24
- 239000000872 buffer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000021736 acetylation Effects 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000003000 inclusion body Anatomy 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000013019 capto adhere Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
。
(a)発現系から生産され、可溶化およびリフォールディングされたインターフェロンを、疎水性相互作用クロマトグラフィーに供するステップであって、インターフェロンがアセチル化形態および非アセチル化形態を含むステップ、および
(b)ステップ(a)で得られたインターフェロンを、本明細書で言及した非アセチル化タンパク質からアセチル化タンパク質を分離する方法に供して、非アセチル化形態のインターフェロンを得ることができるステップ、
を含む。
<遺伝子クローニング、プラスミド設計および細胞培養>
IFN-α遺伝子クローニング、プラスミド設計およびコドン最適化を、組み換えDNA技術によって実施した。組み換えIFN-α-2aは、IFN-α-2aの遺伝子を含有するプラスミドPET30aを有するBL21(DE3)菌(細胞)において、不溶性封入体として発現させた。培養は、5L流加培養において、溶存酸素レベル30%で実施した。1mM IPTGで3時間誘導後、遠心分離によって細胞を培養液から回収した。細胞ペーストを20 mM Tris pH 7.4/ 0.5 mM EDTA緩衝液で洗浄し、その後、超音波処理によって細胞を破砕するために、同じ緩衝液で再懸濁した。IBを遠心分離によって収集した。
IBを適切な体積の50 mM Tris pH7.4/7.0 GdHCl/2% tween 80に溶解し、4 mg/mLのIFN-α-2aを得た。室温で1時間穏やかに撹拌し、完全に溶解した。タンパク質溶液を50 mM Tris pH7.4緩衝液で11倍に希釈した。不溶性のデブリスを、30分間の冷却遠心で除去した。
ジスルフィド酸化に先立ち、50 mM Tris pH7.4緩衝液中の1 mMヨードソベンゾエートを調製した。10μΜヨードソベンゾエートを、1時間ごとに5回タンパク質溶液に導入した(合計50μΜ)。タンパク質溶液を穏やかに撹拌しながら室温でインキュベートした。
1 mM EDTAおよび10 mMメチオニンをタンパク質溶液に加え、続いて固体硫酸アンモニウムを加えて1 Mとした。pHを酢酸でpH6.5に調節した。粒子を遠心分離および濾過で除去した後、クロマトグラフィー精製を以下の通り実施した。
Toyopearl Butyl-650M, 5x5 cm, 流速 25 ml/分、
緩衝液A: 20 mM NaPi pH 6.5/1.0M AmS04/l mM EDTA/ 10 mM メチオニン、
緩衝液B: 20 mM NaPi pH 6.5/1 mM EDTA/ 10 mM メチオニン。
5 mM酢酸アンモニウム緩衝液(pH6.5)を導入し、硫酸アンモニウムを最終伝導率15 mS/cm未満になるまで希釈した。クロマトグラフィー精製を以下の通り実施した。
Capto Adhere 2.6x6 cm、流速6.7 ml/分、
緩衝液C: 50% 酢酸を加えることによる、25 mM酢酸アンモニウム緩衝液(pH 6.5)、
緩衝液D: 5 mM 酢酸
IFN-α-2b生産を実施例1と同じやり方で実施した。IFN-α-2bの全体の収率を表2に示す。本質的にアセチル化アイソフォームを含まない、得られた画分をプールした。IFN-α-2bのクロマトグラムを図3に示す。得られた産物を、それぞれの純度を比較することによって評価した。SDS-PAGE分析の結果を図4に示す。アセチル化IFNの量は、封入体で約20〜30%であった。前記クロマトグラフィーのステップを実施した後、アセチル化IFNは検出されない。
Claims (24)
- アセチル化および非アセチル化タンパク質を含む未精製物をマルチモードクロマトグラフィー支持体に適用するステップ、および
pHを変化させて溶出を行うステップ
を含み、非アセチル化タンパク質からアセチル化タンパク質を分離する方法。 - 前記マルチモードクロマトグラフィー支持体が、疎水性基および陰イオン交換基を含む、請求項1に記載の方法。
- 前記マルチモードクロマトグラフィー支持体の疎水性基が、芳香族基、複素芳香族基または非芳香族疎水性基(アルキル基など)を含む、請求項2に記載の方法。
- 前記疎水性基が、ヘキシル基、ブチル基、フェニル基またはエーテル基である、請求項2に記載の方法。
- 前記マルチモードクロマトグラフィー支持体の陰イオン交換基が、強力な陰イオン交換体である、請求項2に記載の方法。
- 前記マルチモードクロマトグラフィー支持体が、Capto(商標)adhereである、請求項1に記載の方法。
- 前記未精製物が、pH6〜7の間で適用される、請求項1に記載の方法。
- 前記未精製物が、細胞由来である、請求項1に記載の方法。
- 前記未精製物が、原核細胞由来である、請求項1に記載の方法。
- 前記溶出のためのpH変化が、段階的であるまたは勾配を有する、請求項1に記載の方法。
- pH変化が、3〜7の間で実施される、請求項1に記載の方法。
- 前記溶出のpH変化が、3.0〜5.5の間で実施される、請求項1に記載の方法。
- 前記溶出が、酢酸およびアンモニウムを含む溶液で行われる、請求項1に記載の方法。
- インスリン、ソマトトロピン、インターロイキン、インターフェロンまたはソマトメジンの精製において使用される、請求項1に記載の方法。
- (a)発現系から生産され、可溶化されおよびリフォールディングされたインターフェロンを、疎水性相互作用クロマトグラフィーに供するステップであって、当該インターフェロンがアセチル化形態および非アセチル化形態を含むステップ、および
(b)ステップ(a)で得られたインターフェロンを、本明細書で言及した非アセチル化タンパク質からアセチル化タンパク質を分離する方法に供して、非アセチル化形態のインターフェロンを得ることができるステップ、
を含む、発現系で生産された組み換えインターフェロンを精製してその非アセチル化形態を得る方法。 - 前記インターフェロンがインターフェロンαである、請求項15に記載の方法。
- 前記インターフェロンが、IFN-α2aおよびIFN-α2bである、請求項15に記載の方法。
- ステップ(a)において可溶化されリフォールディングされた前記インターフェロンが、発現系における組み換えタンパク質生産によって得られた組み換えインターフェロンの不溶性体の可溶化と、その後得られたインターフェロンを酸化剤の存在下でリフォールディングすることによって得られる、請求項15に記載の方法。
- 前記可溶化が、カオトロピック剤または洗浄剤などの可溶化剤で行われる、請求項18に記載の方法。
- 前記カオトロピック剤が、尿素またはグアニジン塩酸塩である、請求項19に記載の方法。
- 前記洗浄剤が、SDS、N-アセチルトリメチルアンモニウムクロリドまたはN-ラウロイルサルコシンナトリウムである、請求項19に記載の方法。
- 前記可溶化剤が、グアニジン塩酸塩である、請求項19に記載の方法。
- 前記酸化剤が、ヨウ素またはヨードソベンゾエートである、請求項18に記載の方法。
- 酸化剤が、o-ヨードソベンゾエートである、請求項18に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2011/057244 WO2013058762A1 (en) | 2011-10-21 | 2011-10-21 | Separation of acetylated proteins from unacetylated proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014534205A true JP2014534205A (ja) | 2014-12-18 |
JP5948425B2 JP5948425B2 (ja) | 2016-07-06 |
Family
ID=48141212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014537042A Active JP5948425B2 (ja) | 2011-10-21 | 2011-10-21 | 非アセチル化タンパク質からのアセチル化タンパク質の分離 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2768844B1 (ja) |
JP (1) | JP5948425B2 (ja) |
CN (1) | CN103930433A (ja) |
TW (1) | TWI612056B (ja) |
WO (1) | WO2013058762A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08503227A (ja) * | 1993-03-05 | 1996-04-09 | シェリング・コーポレーション | ヒトインターロイキン−10の精製 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
-
2011
- 2011-10-21 WO PCT/US2011/057244 patent/WO2013058762A1/en active Application Filing
- 2011-10-21 CN CN201180074283.9A patent/CN103930433A/zh active Pending
- 2011-10-21 EP EP11874171.9A patent/EP2768844B1/en active Active
- 2011-10-21 JP JP2014537042A patent/JP5948425B2/ja active Active
-
2012
- 2012-10-22 TW TW101138958A patent/TWI612056B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08503227A (ja) * | 1993-03-05 | 1996-04-09 | シェリング・コーポレーション | ヒトインターロイキン−10の精製 |
Non-Patent Citations (2)
Title |
---|
JPN6015038661; GE Healthcare Data File Mutimodal media Capto adhere [online], [平成27年9月15日検索], GEヘルスケアバイオサイエンス株式会社 * |
JPN6015038663; Biotechnol.Appl.Biochem. Vol.33, 2001, p.173-182 * |
Also Published As
Publication number | Publication date |
---|---|
EP2768844A1 (en) | 2014-08-27 |
EP2768844B1 (en) | 2016-04-27 |
TWI612056B (zh) | 2018-01-21 |
WO2013058762A1 (en) | 2013-04-25 |
JP5948425B2 (ja) | 2016-07-06 |
EP2768844A4 (en) | 2015-03-25 |
TW201323436A (zh) | 2013-06-16 |
CN103930433A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gaberc-Porekar et al. | Perspectives of immobilized-metal affinity chromatography | |
EP2726496B1 (en) | Method for separation of monomeric polypeptides from aggregated polypeptides | |
EP3040346B1 (en) | Process for the purification of granulocyte colony stimulating factor, g-csf | |
DK175251B1 (da) | Renfremstilling af erythropoietin | |
WO2008006899A1 (en) | One step imac (mcac) purification of proteins | |
Sánchez-Trasviña et al. | Purification of modified therapeutic proteins available on the market: An analysis of chromatography-based strategies | |
WO2006097944A2 (en) | Process for the purification of recombinant granulocyte-colony stimulating factor | |
AU2002335952B2 (en) | Method of protein purification | |
Ueda et al. | Ni (II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts | |
JP6232130B2 (ja) | ダルベポエチンアルファの精製方法 | |
JP5948425B2 (ja) | 非アセチル化タンパク質からのアセチル化タンパク質の分離 | |
RU2346002C2 (ru) | Способ очистки интерферона бета человека | |
Wang et al. | Renaturation with simultaneous purification of rhG‐CSF from Escherichia coli by ion exchange chromatography | |
WO2020234742A1 (en) | Granulocyte colony stimulating factor purification | |
Fee | Protein conjugates purification and characterization | |
US20140228539A1 (en) | Separation of acetylated proteins from unacetylated proteins | |
EP2905289A1 (en) | Method for purifying teriparatide (PTH1-34) | |
Wilson | Purification of proteins/peptides for structural studies | |
WO2011151716A1 (en) | Process for the purification of recombinant human il-11 | |
KR100400638B1 (ko) | 재조합 인간 성장호르몬 유사체의 분리방법 | |
JP4146728B2 (ja) | 非分岐アルキル末端ジオールを使用する分子の精製方法 | |
Hancock et al. | Biochemical applications of preparative liquid chromatography | |
WO2005077973A1 (en) | Purification of recombinant human proteins | |
JPH01503038A (ja) | ガンマインターフェロン活性を有する新規ポリペプチド | |
Bai et al. | Studies on the refolding of the reduced-denatured insulin with size exclusion chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160606 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5948425 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |